Cargando…
A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy
COL4A5 mutations are a known cause of Alport syndrome, which typically manifests with haematuria, hearing loss and ocular symptoms. Here we report on a 16-year-old male patient with a negative family history who presented with proteinuria, progressive renal failure and haemolysis, but without overt...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655797/ https://www.ncbi.nlm.nih.gov/pubmed/26613025 http://dx.doi.org/10.1093/ckj/sfv091 |
_version_ | 1782402221329088512 |
---|---|
author | Wuttke, Matthias Seidl, Maximilian Malinoc, Angelica Prischl, Friedrich C. Kuehn, E. Wolfgang Walz, Gerd Köttgen, Anna |
author_facet | Wuttke, Matthias Seidl, Maximilian Malinoc, Angelica Prischl, Friedrich C. Kuehn, E. Wolfgang Walz, Gerd Köttgen, Anna |
author_sort | Wuttke, Matthias |
collection | PubMed |
description | COL4A5 mutations are a known cause of Alport syndrome, which typically manifests with haematuria, hearing loss and ocular symptoms. Here we report on a 16-year-old male patient with a negative family history who presented with proteinuria, progressive renal failure and haemolysis, but without overt haematuria or hearing loss. A renal biopsy revealed features of atypical IgA nephropathy, while a second biopsy a year later showed features of focal segmental glomerulosclerosis, but was finally diagnosed as chronic thrombotic microangiopathy. Targeted sequencing of candidate genes for steroid-resistant nephrotic syndrome and congenital thrombotic microangiopathy was negative. Despite all therapeutic efforts, including angiotensin-converting enzyme inhibition, immunosuppressive therapy, plasma exchanges and rituximab, the patient progressed to end-stage renal disease. When a male cousin presented with nephrotic syndrome years later, whole-exome sequencing identified a shared disruptive COL4A5 mutation (p.F222C) that showed X-linked segregation. Thus, mutations in COL4A5 give rise to a broader spectrum of clinical presentation than commonly suspected, highlighting the benefits of comprehensive rather than candidate genetic testing in young patients with otherwise unexplained glomerular disease. Our results are in line with an increasing number of atypical presentations of single-gene disorders identified through genome-wide sequencing. |
format | Online Article Text |
id | pubmed-4655797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46557972015-11-26 A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy Wuttke, Matthias Seidl, Maximilian Malinoc, Angelica Prischl, Friedrich C. Kuehn, E. Wolfgang Walz, Gerd Köttgen, Anna Clin Kidney J Contents COL4A5 mutations are a known cause of Alport syndrome, which typically manifests with haematuria, hearing loss and ocular symptoms. Here we report on a 16-year-old male patient with a negative family history who presented with proteinuria, progressive renal failure and haemolysis, but without overt haematuria or hearing loss. A renal biopsy revealed features of atypical IgA nephropathy, while a second biopsy a year later showed features of focal segmental glomerulosclerosis, but was finally diagnosed as chronic thrombotic microangiopathy. Targeted sequencing of candidate genes for steroid-resistant nephrotic syndrome and congenital thrombotic microangiopathy was negative. Despite all therapeutic efforts, including angiotensin-converting enzyme inhibition, immunosuppressive therapy, plasma exchanges and rituximab, the patient progressed to end-stage renal disease. When a male cousin presented with nephrotic syndrome years later, whole-exome sequencing identified a shared disruptive COL4A5 mutation (p.F222C) that showed X-linked segregation. Thus, mutations in COL4A5 give rise to a broader spectrum of clinical presentation than commonly suspected, highlighting the benefits of comprehensive rather than candidate genetic testing in young patients with otherwise unexplained glomerular disease. Our results are in line with an increasing number of atypical presentations of single-gene disorders identified through genome-wide sequencing. Oxford University Press 2015-12 2015-09-29 /pmc/articles/PMC4655797/ /pubmed/26613025 http://dx.doi.org/10.1093/ckj/sfv091 Text en © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Contents Wuttke, Matthias Seidl, Maximilian Malinoc, Angelica Prischl, Friedrich C. Kuehn, E. Wolfgang Walz, Gerd Köttgen, Anna A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
title | A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
title_full | A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
title_fullStr | A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
title_full_unstemmed | A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
title_short | A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
title_sort | col4a5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy |
topic | Contents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655797/ https://www.ncbi.nlm.nih.gov/pubmed/26613025 http://dx.doi.org/10.1093/ckj/sfv091 |
work_keys_str_mv | AT wuttkematthias acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT seidlmaximilian acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT malinocangelica acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT prischlfriedrichc acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT kuehnewolfgang acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT walzgerd acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT kottgenanna acol4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT wuttkematthias col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT seidlmaximilian col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT malinocangelica col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT prischlfriedrichc col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT kuehnewolfgang col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT walzgerd col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy AT kottgenanna col4a5mutationwithglomerulardiseaseandsignsofchronicthromboticmicroangiopathy |